United States Hematological Malignancies Disease Market Report 2018
![](/report_cover/6975/united-states-hematological-malignancies-disease-market-report-2018_qyresearch_en.gif)
In this report, the United States Hematological Malignancies Disease market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report splits the United States market into seven regions:
Geographically, this report splits the United States market into seven regions:
- The West
- Southwest
- The Middle Atlantic
- New England
- The South
- The Midwest
- with sales (volume), revenue (value), market share and growth rate of Hematological Malignancies Disease in these regions, from 2013 to 2025 (forecast).
- Affymetrix
- SkylineDx
- AgenaBio
- Signal Genetics
- Cancer Genetics Inc
- Illumina
- NeoGenomics
- Exiqon
- Regulus Therapeutics
- Rosetta Genomics
- Sequenta
- Takeda Pharma
- Celgene
- Amgen
- Ono Pharma
- Abbott
- BMS
- Mundipharma
- Novartis
- MorphoSys
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Leukemia
- Lymphoma
- Myeloma
United States Hematological Malignancies Disease Market Report 2018
1 HEMATOLOGICAL MALIGNANCIES DISEASE OVERVIEW
1.1 Product Overview and Scope of Hematological Malignancies Disease
1.2 Classification of Hematological Malignancies Disease by Product Category
1.2.1 United States Hematological Malignancies Disease Market Size (Sales Volume) Comparison by Type (2013-2025)
1.2.2 United States Hematological Malignancies Disease Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Targeted Therapy
1.3 United States Hematological Malignancies Disease Market by Application/End Users
1.3.1 United States Hematological Malignancies Disease Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Myeloma
1.4 United States Hematological Malignancies Disease Market by Region
1.4.1 United States Hematological Malignancies Disease Market Size (Value) Comparison by Region (2013-2025)
1.4.2 The West Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.3 Southwest Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.4 The Middle Atlantic Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.5 New England Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.6 The South Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.7 The Midwest Hematological Malignancies Disease Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Hematological Malignancies Disease (2013-2025)
1.5.1 United States Hematological Malignancies Disease Sales and Growth Rate (2013-2025)
1.5.2 United States Hematological Malignancies Disease Revenue and Growth Rate (2013-2025)
2 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE MARKET COMPETITION BY PLAYERS/SUPPLIERS
2.1 United States Hematological Malignancies Disease Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Hematological Malignancies Disease Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Hematological Malignancies Disease Average Price by Players/Suppliers (2013-2018)
2.4 United States Hematological Malignancies Disease Market Competitive Situation and Trends
2.4.1 United States Hematological Malignancies Disease Market Concentration Rate
2.4.2 United States Hematological Malignancies Disease Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Hematological Malignancies Disease Manufacturing Base Distribution, Sales Area, Product Type
3 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)
3.1 United States Hematological Malignancies Disease Sales and Market Share by Region (2013-2018)
3.2 United States Hematological Malignancies Disease Revenue and Market Share by Region (2013-2018)
3.3 United States Hematological Malignancies Disease Price by Region (2013-2018)
4 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)
4.1 United States Hematological Malignancies Disease Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Hematological Malignancies Disease Revenue and Market Share by Type (2013-2018)
4.3 United States Hematological Malignancies Disease Price by Type (2013-2018)
4.4 United States Hematological Malignancies Disease Sales Growth Rate by Type (2013-2018)
5 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE SALES (VOLUME) BY APPLICATION (2013-2018)
5.1 United States Hematological Malignancies Disease Sales and Market Share by Application (2013-2018)
5.2 United States Hematological Malignancies Disease Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities
6 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE PLAYERS/SUPPLIERS PROFILES AND SALES DATA
6.1 Affymetrix
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Hematological Malignancies Disease Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Affymetrix Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Main Business/Business Overview
6.2 SkylineDx
6.2.2 Hematological Malignancies Disease Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 SkylineDx Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Main Business/Business Overview
6.3 AgenaBio
6.3.2 Hematological Malignancies Disease Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 AgenaBio Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Main Business/Business Overview
6.4 Signal Genetics
6.4.2 Hematological Malignancies Disease Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Signal Genetics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Main Business/Business Overview
6.5 Cancer Genetics Inc
6.5.2 Hematological Malignancies Disease Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Cancer Genetics Inc Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Main Business/Business Overview
6.6 Illumina
6.6.2 Hematological Malignancies Disease Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Illumina Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Main Business/Business Overview
6.7 NeoGenomics
6.7.2 Hematological Malignancies Disease Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 NeoGenomics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Main Business/Business Overview
6.8 Exiqon
6.8.2 Hematological Malignancies Disease Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Exiqon Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.8.4 Main Business/Business Overview
6.9 Regulus Therapeutics
6.9.2 Hematological Malignancies Disease Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Regulus Therapeutics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Main Business/Business Overview
6.10 Rosetta Genomics
6.10.2 Hematological Malignancies Disease Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Rosetta Genomics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.10.4 Main Business/Business Overview
6.11 Sequenta
6.12 Takeda Pharma
6.13 Celgene
6.14 Amgen
6.15 Ono Pharma
6.16 Abbott
6.17 BMS
6.18 Mundipharma
6.19 Novartis
6.20 MorphoSys
7 HEMATOLOGICAL MALIGNANCIES DISEASE MANUFACTURING COST ANALYSIS
7.1 Hematological Malignancies Disease Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Hematological Malignancies Disease
8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
8.1 Hematological Malignancies Disease Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Hematological Malignancies Disease Major Manufacturers in 2017
8.4 Downstream Buyers
9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 MARKET EFFECT FACTORS ANALYSIS
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)
11.1 United States Hematological Malignancies Disease Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Hematological Malignancies Disease Sales Volume Forecast by Type (2018-2025)
11.3 United States Hematological Malignancies Disease Sales Volume Forecast by Application (2018-2025)
11.4 United States Hematological Malignancies Disease Sales Volume Forecast by Region (2018-2025)
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
The report requires updating with new data and is sent in 2-3 business days after order is placed.
1 HEMATOLOGICAL MALIGNANCIES DISEASE OVERVIEW
1.1 Product Overview and Scope of Hematological Malignancies Disease
1.2 Classification of Hematological Malignancies Disease by Product Category
1.2.1 United States Hematological Malignancies Disease Market Size (Sales Volume) Comparison by Type (2013-2025)
1.2.2 United States Hematological Malignancies Disease Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Targeted Therapy
1.3 United States Hematological Malignancies Disease Market by Application/End Users
1.3.1 United States Hematological Malignancies Disease Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Myeloma
1.4 United States Hematological Malignancies Disease Market by Region
1.4.1 United States Hematological Malignancies Disease Market Size (Value) Comparison by Region (2013-2025)
1.4.2 The West Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.3 Southwest Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.4 The Middle Atlantic Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.5 New England Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.6 The South Hematological Malignancies Disease Status and Prospect (2013-2025)
1.4.7 The Midwest Hematological Malignancies Disease Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Hematological Malignancies Disease (2013-2025)
1.5.1 United States Hematological Malignancies Disease Sales and Growth Rate (2013-2025)
1.5.2 United States Hematological Malignancies Disease Revenue and Growth Rate (2013-2025)
2 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE MARKET COMPETITION BY PLAYERS/SUPPLIERS
2.1 United States Hematological Malignancies Disease Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Hematological Malignancies Disease Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Hematological Malignancies Disease Average Price by Players/Suppliers (2013-2018)
2.4 United States Hematological Malignancies Disease Market Competitive Situation and Trends
2.4.1 United States Hematological Malignancies Disease Market Concentration Rate
2.4.2 United States Hematological Malignancies Disease Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Hematological Malignancies Disease Manufacturing Base Distribution, Sales Area, Product Type
3 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)
3.1 United States Hematological Malignancies Disease Sales and Market Share by Region (2013-2018)
3.2 United States Hematological Malignancies Disease Revenue and Market Share by Region (2013-2018)
3.3 United States Hematological Malignancies Disease Price by Region (2013-2018)
4 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)
4.1 United States Hematological Malignancies Disease Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Hematological Malignancies Disease Revenue and Market Share by Type (2013-2018)
4.3 United States Hematological Malignancies Disease Price by Type (2013-2018)
4.4 United States Hematological Malignancies Disease Sales Growth Rate by Type (2013-2018)
5 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE SALES (VOLUME) BY APPLICATION (2013-2018)
5.1 United States Hematological Malignancies Disease Sales and Market Share by Application (2013-2018)
5.2 United States Hematological Malignancies Disease Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities
6 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE PLAYERS/SUPPLIERS PROFILES AND SALES DATA
6.1 Affymetrix
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Hematological Malignancies Disease Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Affymetrix Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Main Business/Business Overview
6.2 SkylineDx
6.2.2 Hematological Malignancies Disease Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 SkylineDx Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Main Business/Business Overview
6.3 AgenaBio
6.3.2 Hematological Malignancies Disease Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 AgenaBio Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Main Business/Business Overview
6.4 Signal Genetics
6.4.2 Hematological Malignancies Disease Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Signal Genetics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Main Business/Business Overview
6.5 Cancer Genetics Inc
6.5.2 Hematological Malignancies Disease Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Cancer Genetics Inc Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Main Business/Business Overview
6.6 Illumina
6.6.2 Hematological Malignancies Disease Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Illumina Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Main Business/Business Overview
6.7 NeoGenomics
6.7.2 Hematological Malignancies Disease Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 NeoGenomics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Main Business/Business Overview
6.8 Exiqon
6.8.2 Hematological Malignancies Disease Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Exiqon Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.8.4 Main Business/Business Overview
6.9 Regulus Therapeutics
6.9.2 Hematological Malignancies Disease Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Regulus Therapeutics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Main Business/Business Overview
6.10 Rosetta Genomics
6.10.2 Hematological Malignancies Disease Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Rosetta Genomics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2013-2018)
6.10.4 Main Business/Business Overview
6.11 Sequenta
6.12 Takeda Pharma
6.13 Celgene
6.14 Amgen
6.15 Ono Pharma
6.16 Abbott
6.17 BMS
6.18 Mundipharma
6.19 Novartis
6.20 MorphoSys
7 HEMATOLOGICAL MALIGNANCIES DISEASE MANUFACTURING COST ANALYSIS
7.1 Hematological Malignancies Disease Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Hematological Malignancies Disease
8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
8.1 Hematological Malignancies Disease Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Hematological Malignancies Disease Major Manufacturers in 2017
8.4 Downstream Buyers
9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 MARKET EFFECT FACTORS ANALYSIS
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 UNITED STATES HEMATOLOGICAL MALIGNANCIES DISEASE MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)
11.1 United States Hematological Malignancies Disease Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Hematological Malignancies Disease Sales Volume Forecast by Type (2018-2025)
11.3 United States Hematological Malignancies Disease Sales Volume Forecast by Application (2018-2025)
11.4 United States Hematological Malignancies Disease Sales Volume Forecast by Region (2018-2025)
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES
Figure Product Picture of Hematological Malignancies Disease
Figure United States Hematological Malignancies Disease Market Size (K Units) by Type (2013-2025)
Figure United States Hematological Malignancies Disease Sales Volume Market Share by Type (Product Category) in 2017
Figure Chemotherapy Product Picture
Figure Immunotherapy Product Picture
Figure Targeted Therapy Product Picture
Figure United States Hematological Malignancies Disease Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Hematological Malignancies Disease by Application in 2017
Figure Leukemia Examples
Table Key Downstream Customer in Leukemia
Figure Lymphoma Examples
Table Key Downstream Customer in Lymphoma
Figure Myeloma Examples
Table Key Downstream Customer in Myeloma
Figure United States Hematological Malignancies Disease Market Size (Million USD) by Region (2013-2025)
Figure The West Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Hematological Malignancies Disease Sales (K Units) and Growth Rate (2013-2025)
Figure United States Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Hematological Malignancies Disease Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Hematological Malignancies Disease Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Hematological Malignancies Disease Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Hematological Malignancies Disease Sales Share by Players/Suppliers
Figure 2017 United States Hematological Malignancies Disease Sales Share by Players/Suppliers
Figure United States Hematological Malignancies Disease Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Hematological Malignancies Disease Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Hematological Malignancies Disease Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Hematological Malignancies Disease Revenue Share by Players/Suppliers
Figure 2017 United States Hematological Malignancies Disease Revenue Share by Players/Suppliers
Table United States Market Hematological Malignancies Disease Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Hematological Malignancies Disease Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Hematological Malignancies Disease Market Share of Top 3 Players/Suppliers
Figure United States Hematological Malignancies Disease Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Hematological Malignancies Disease Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Hematological Malignancies Disease Product Category
Table United States Hematological Malignancies Disease Sales (K Units) by Region (2013-2018)
Table United States Hematological Malignancies Disease Sales Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Sales Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Region in 2017
Table United States Hematological Malignancies Disease Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Hematological Malignancies Disease Revenue Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Revenue Market Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Revenue Market Share by Region in 2017
Table United States Hematological Malignancies Disease Price (USD/Unit) by Region (2013-2018)
Table United States Hematological Malignancies Disease Sales (K Units) by Type (2013-2018)
Table United States Hematological Malignancies Disease Sales Share by Type (2013-2018)
Figure United States Hematological Malignancies Disease Sales Share by Type (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Type in 2017
Table United States Hematological Malignancies Disease Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Hematological Malignancies Disease Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Hematological Malignancies Disease by Type (2013-2018)
Figure Revenue Market Share of Hematological Malignancies Disease by Type in 2017
Table United States Hematological Malignancies Disease Price (USD/Unit) by Types (2013-2018)
Figure United States Hematological Malignancies Disease Sales Growth Rate by Type (2013-2018)
Table United States Hematological Malignancies Disease Sales (K Units) by Application (2013-2018)
Table United States Hematological Malignancies Disease Sales Market Share by Application (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Application (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Application in 2017
Table United States Hematological Malignancies Disease Sales Growth Rate by Application (2013-2018)
Figure United States Hematological Malignancies Disease Sales Growth Rate by Application (2013-2018)
Table Affymetrix Basic Information List
Table Affymetrix Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Affymetrix Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Affymetrix Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Affymetrix Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table SkylineDx Basic Information List
Table SkylineDx Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure SkylineDx Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure SkylineDx Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure SkylineDx Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table AgenaBio Basic Information List
Table AgenaBio Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure AgenaBio Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure AgenaBio Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure AgenaBio Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Signal Genetics Basic Information List
Table Signal Genetics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Signal Genetics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Signal Genetics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Signal Genetics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Cancer Genetics Inc Basic Information List
Table Cancer Genetics Inc Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Cancer Genetics Inc Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Cancer Genetics Inc Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Cancer Genetics Inc Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Illumina Basic Information List
Table Illumina Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Illumina Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Illumina Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Illumina Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table NeoGenomics Basic Information List
Table NeoGenomics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure NeoGenomics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure NeoGenomics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure NeoGenomics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Exiqon Basic Information List
Table Exiqon Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Exiqon Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Exiqon Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Exiqon Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Regulus Therapeutics Basic Information List
Table Regulus Therapeutics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Regulus Therapeutics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Regulus Therapeutics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Regulus Therapeutics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Rosetta Genomics Basic Information List
Table Rosetta Genomics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Rosetta Genomics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Rosetta Genomics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Rosetta Genomics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Sequenta Basic Information List
Table Takeda Pharma Basic Information List
Table Celgene Basic Information List
Table Amgen Basic Information List
Table Ono Pharma Basic Information List
Table Abbott Basic Information List
Table BMS Basic Information List
Table Mundipharma Basic Information List
Table Novartis Basic Information List
Table MorphoSys Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Hematological Malignancies Disease
Figure Manufacturing Process Analysis of Hematological Malignancies Disease
Figure Hematological Malignancies Disease Industrial Chain Analysis
Table Raw Materials Sources of Hematological Malignancies Disease Major Players/Suppliers in 2017
Table Major Buyers of Hematological Malignancies Disease
Table Distributors/Traders List
Figure United States Hematological Malignancies Disease Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Hematological Malignancies Disease Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Hematological Malignancies Disease Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Type in 2025
Table United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Application in 2025
Table United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Hematological Malignancies Disease Sales Volume Share Forecast by Region (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume Share Forecast by Region (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
Figure Product Picture of Hematological Malignancies Disease
Figure United States Hematological Malignancies Disease Market Size (K Units) by Type (2013-2025)
Figure United States Hematological Malignancies Disease Sales Volume Market Share by Type (Product Category) in 2017
Figure Chemotherapy Product Picture
Figure Immunotherapy Product Picture
Figure Targeted Therapy Product Picture
Figure United States Hematological Malignancies Disease Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Hematological Malignancies Disease by Application in 2017
Figure Leukemia Examples
Table Key Downstream Customer in Leukemia
Figure Lymphoma Examples
Table Key Downstream Customer in Lymphoma
Figure Myeloma Examples
Table Key Downstream Customer in Myeloma
Figure United States Hematological Malignancies Disease Market Size (Million USD) by Region (2013-2025)
Figure The West Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Hematological Malignancies Disease Sales (K Units) and Growth Rate (2013-2025)
Figure United States Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Hematological Malignancies Disease Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Hematological Malignancies Disease Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Hematological Malignancies Disease Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Hematological Malignancies Disease Sales Share by Players/Suppliers
Figure 2017 United States Hematological Malignancies Disease Sales Share by Players/Suppliers
Figure United States Hematological Malignancies Disease Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Hematological Malignancies Disease Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Hematological Malignancies Disease Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Hematological Malignancies Disease Revenue Share by Players/Suppliers
Figure 2017 United States Hematological Malignancies Disease Revenue Share by Players/Suppliers
Table United States Market Hematological Malignancies Disease Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Hematological Malignancies Disease Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Hematological Malignancies Disease Market Share of Top 3 Players/Suppliers
Figure United States Hematological Malignancies Disease Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Hematological Malignancies Disease Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Hematological Malignancies Disease Product Category
Table United States Hematological Malignancies Disease Sales (K Units) by Region (2013-2018)
Table United States Hematological Malignancies Disease Sales Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Sales Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Region in 2017
Table United States Hematological Malignancies Disease Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Hematological Malignancies Disease Revenue Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Revenue Market Share by Region (2013-2018)
Figure United States Hematological Malignancies Disease Revenue Market Share by Region in 2017
Table United States Hematological Malignancies Disease Price (USD/Unit) by Region (2013-2018)
Table United States Hematological Malignancies Disease Sales (K Units) by Type (2013-2018)
Table United States Hematological Malignancies Disease Sales Share by Type (2013-2018)
Figure United States Hematological Malignancies Disease Sales Share by Type (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Type in 2017
Table United States Hematological Malignancies Disease Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Hematological Malignancies Disease Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Hematological Malignancies Disease by Type (2013-2018)
Figure Revenue Market Share of Hematological Malignancies Disease by Type in 2017
Table United States Hematological Malignancies Disease Price (USD/Unit) by Types (2013-2018)
Figure United States Hematological Malignancies Disease Sales Growth Rate by Type (2013-2018)
Table United States Hematological Malignancies Disease Sales (K Units) by Application (2013-2018)
Table United States Hematological Malignancies Disease Sales Market Share by Application (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Application (2013-2018)
Figure United States Hematological Malignancies Disease Sales Market Share by Application in 2017
Table United States Hematological Malignancies Disease Sales Growth Rate by Application (2013-2018)
Figure United States Hematological Malignancies Disease Sales Growth Rate by Application (2013-2018)
Table Affymetrix Basic Information List
Table Affymetrix Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Affymetrix Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Affymetrix Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Affymetrix Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table SkylineDx Basic Information List
Table SkylineDx Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure SkylineDx Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure SkylineDx Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure SkylineDx Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table AgenaBio Basic Information List
Table AgenaBio Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure AgenaBio Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure AgenaBio Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure AgenaBio Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Signal Genetics Basic Information List
Table Signal Genetics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Signal Genetics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Signal Genetics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Signal Genetics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Cancer Genetics Inc Basic Information List
Table Cancer Genetics Inc Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Cancer Genetics Inc Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Cancer Genetics Inc Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Cancer Genetics Inc Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Illumina Basic Information List
Table Illumina Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Illumina Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Illumina Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Illumina Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table NeoGenomics Basic Information List
Table NeoGenomics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure NeoGenomics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure NeoGenomics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure NeoGenomics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Exiqon Basic Information List
Table Exiqon Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Exiqon Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Exiqon Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Exiqon Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Regulus Therapeutics Basic Information List
Table Regulus Therapeutics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Regulus Therapeutics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Regulus Therapeutics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Regulus Therapeutics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Rosetta Genomics Basic Information List
Table Rosetta Genomics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Rosetta Genomics Hematological Malignancies Disease Sales Growth Rate (2013-2018)
Figure Rosetta Genomics Hematological Malignancies Disease Sales Market Share in United States (2013-2018)
Figure Rosetta Genomics Hematological Malignancies Disease Revenue Market Share in United States (2013-2018)
Table Sequenta Basic Information List
Table Takeda Pharma Basic Information List
Table Celgene Basic Information List
Table Amgen Basic Information List
Table Ono Pharma Basic Information List
Table Abbott Basic Information List
Table BMS Basic Information List
Table Mundipharma Basic Information List
Table Novartis Basic Information List
Table MorphoSys Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Hematological Malignancies Disease
Figure Manufacturing Process Analysis of Hematological Malignancies Disease
Figure Hematological Malignancies Disease Industrial Chain Analysis
Table Raw Materials Sources of Hematological Malignancies Disease Major Players/Suppliers in 2017
Table Major Buyers of Hematological Malignancies Disease
Table Distributors/Traders List
Figure United States Hematological Malignancies Disease Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Hematological Malignancies Disease Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Hematological Malignancies Disease Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Type in 2025
Table United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Application in 2025
Table United States Hematological Malignancies Disease Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Hematological Malignancies Disease Sales Volume Share Forecast by Region (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume Share Forecast by Region (2018-2025)
Figure United States Hematological Malignancies Disease Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources